“…Compared to studies with a longer follow-up [19,20,25,26] and accordingly higher mean age (between 32 and 41 years), our results were in range of the published data in all of the quality of life-related domains of the SRS-24 (pain, selfimage, and general function) but in the domain satisfaction with treatment where we received slightly more positive feedback from our study population (this study: MS 4.2 vs compared studies: MS 3.5-3.8). In contrast to the compared studies [19,20,25,26], where FTRB was the only treatment, in our study population continuous PSSE, supervised at regular intervals, was standard of care, as in a short-term follow-up study [27] (satisfaction with treatment MS 3.9).…”